Pamplona Therapeutics is advancing next‑generation targeted protein degradation (TPD) therapies to address major unmet needs across autoimmune, oncology, and infectious diseases. Our proprietary AI‑driven discovery platform, ASTRIDE®, integrates target structure prediction, high‑throughput molecular generation and docking, and ubiquitination assessment into a unified engine for rapid degrader design. Leveraging ASTRIDE®, Pamplona advanced its first autoimmune-focused preclinical candidate within 18 months of founding and submitted its first Investigational New Drug (IND) application in November 2025—just three years after initiating operations. Building on this momentum, we are expanding our platform to unlock previously undruggable targets and deliver transformative therapies for global disease challenges.